Updated Jul 16, 2026
Lind Kevin Robert has filed 2 SEC Form 4 filings across 1 company in the last 90 days.
Kevin Robert Lind is an executive in the biotechnology sector, currently serving as the CEO of Avalo Therapeutics, Inc. He has held various leadership roles, including President and Director. His work focuses on advancing clinical-stage therapies for immune dysregulation.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2024-12-02 | LBPH | Longboard Pharmaceuticals, Inc. | J — Other acquisition / disposition | 363.7K | $60.00 | $21.82M |
| 2024-11-13 | LBPH | Longboard Pharmaceuticals, Inc. | G — Bona-fide gift | 80.0K | $0.00 | |
| 2024-11-13 | LBPH | Longboard Pharmaceuticals, Inc. | M — Option exercise | 12.8K | $3.12 | $40K |
Kevin Robert Lind is an executive in the biotechnology sector, currently serving as the CEO of Avalo Therapeutics, Inc. He has held various leadership roles, including President and Director. His work focuses on advancing clinical-stage therapies for immune dysregulation.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Lind Kevin Robert profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.